$达维塔保健(DVA)$ Oct 11 (Reuters) - Shares of dialysis service providers fell sharply on Wednesday after Novo Nordisk's (NOVOb.CO) Ozempic showed early signs of success in delaying the progression of kidney disease in diabetes patients.

Colorado-based DaVita's (DVA.N) shares fell about 16%, to $76.62, and U.S.-listed shares of German rival Fresenius Medical (FMEG.DE) were down 16.7%, to $17.44, in early trading. Shares of U.S.-based Baxter International (BAX.N), which makes products used by dialysis therapy providers, also fell 5.8%, to $费森尤斯医疗(FMS)$